Evidence map›Paper›PMID 36699443›Full record

ArticleNanotechnology, science and applications2023

Graphene Oxide Decreases Pro-Inflammatory Proteins Production in Skeletal Muscle Cells Exposed to SARS-CoV-2 Spike Protein.

Jaśmina Bałaban, Mateusz Wierzbicki, Marlena Zielińska-Górska, Malwina Sosnowska, Karolina Daniluk, Sławomir Jaworski, Piotr Koczoń, Dominik Cysewski, André Chwalibog, Ewa Sawosz

Open access · goldAbstract read
In one paragraph

Article in Nanotechnology, science and applications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Fullerenol CInternational journal of nanomedicine · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Jaśmina BałabanDepartment of Nanobiotechnology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland.
Mateusz WierzbickiDepartment of Nanobiotechnology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland.
Marlena Zielińska-GórskaDepartment of Nanobiotechnology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland.
Malwina SosnowskaDepartment of Nanobiotechnology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland.ORCID 0000-0002-1882-0846
Karolina DanilukDepartment of Nanobiotechnology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland.ORCID 0000-0002-7899-3431
Sławomir JaworskiDepartment of Nanobiotechnology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland.ORCID 0000-0002-4619-941X
Piotr KoczońDepartment of Chemistry, Institute of Food Sciences, Warsaw University of Life Sciences, Warsaw, Poland.
Dominik CysewskiClinical Research Centre, Medical University of Bialystok, Białystok, Poland.
André ChwalibogDepartment of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg, Denmark.ORCID 0000-0001-8150-2392
Ewa SawoszDepartment of Nanobiotechnology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland.
Warsaw University of Life Sciences · PLMedical University of Białystok · PLUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: The experiments aimed to document the presence of the ACE2 receptor on human muscle cells and the effects of the interaction of these cells with the spike protein of the SARS-CoV-2 virus in terms of induction of pro-inflammatory proteins, as well as to assess the possibility of reducing the pool of these proteins with the use of graphene oxide (GO) flakes. Methods: Human Skeletal Myoblast (HSkM), purchased from Gibco were maintained in standard condition according to the manufacturer's instruction. The cells were divided into 4 groups; 1. C-control, 2. S-with addition of spike protein, 3. GO-with the addition of graphene oxide, 4. GO-S-with addition of GO followed by the addition of S protein. Protein S (PX-COV-P049) was purchased from ProteoGenix (France). GO was obtained from Advanced Graphene Products (Zielona Gora, Poland). The influence of all the factors on the morphology of cells was investigated using light and confocal microscopy. ACE2 protein expression on muscle cells was visualized and 40 pro-inflammatory cytokines were investigated using the membrane antibody array method. The protein profile of the lysate of cells from individual groups was also analyzed by mass spectrometry. Conclusion: The experiments confirmed the presence of the ACE2 receptor in human skeletal muscle cells. It has also been documented that the SARS-CoV-2 virus spike protein influences the activation of selected pro-inflammatory proteins that promote cytokine storm and oxidative stress in muscle cells. The use of low levels of graphene oxide does not adversely affect muscle cells, reducing the levels of most proteins, including pro-inflammatory proteins. It can be assumed that GO may support anti-inflammatory therapy in muscles by scavenging proteins that activate cytokine storm.

Indexed as

ACE2cytokine stormgraphene oxidemuscle cellsSARS-CoV-2virus spike protein S

Identifiers

PMID36699443
PMCPMC9869801
OpenAlexW4318168939

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.